Company profile: HepaRegeniX
1.1 - Company Overview
Company description
- Provider of drug candidates targeting MKK4 to restore hepatocyte regeneration for acute and chronic liver diseases. Pipeline includes HRX-0215, a first-in-class MKK4 inhibitor in clinical trials, and HRX-0233, a second MKK4 inhibitor under preclinical collaborations for cancer combination therapy.
Products and services
- HRX-0215: HepaRegeniX engineers HRX-0215, a first-in-class MKK4 inhibitor for acute and chronic liver diseases, in clinical trials, aimed at restoring hepatocyte regenerative capacity
- MKK4-guided Hepatocyte Regeneration Program: HepaRegeniX architects drugs for acute and chronic liver diseases restoring hepatocyte regenerative capacity, founded on Tübingen research identifying MAP kinase kinase 4 as key
- HRX-0233: HepaRegeniX develops HRX-0233, a preclinical second MKK4 inhibitor being explored for use in cancer combination therapy through preclinical collaborations
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to HepaRegeniX
OrsoBio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for severe metabolic disorders, including TLC-3595 (selective ACC2 inhibitor) to improve insulin sensitivity in type 2 diabetes; TLC-2716 (liver-targeted LXR inverse agonist) to lower plasma triglycerides and cholesterol in severe dyslipidemias; mitochondrial protonophores (TLC-6740, TLC-1235) to increase energy expenditure; and an ACMSD inhibitor to augment NAD+ and mitochondrial function in liver/kidney dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OrsoBio company profile →
Liminal Biosciences
HQ: Canada
Website
- Description: Provider of state-of-the-art bio-separation technologies and therapeutic programs, including LMNL6511, a selective GPR84 antagonist for inflammatory and fibrotic diseases expected to enter Phase 1 clinical trials; an OXER1 antagonist in preclinical for eosinophilic-driven diseases (asthma, atopic dermatitis); and a discovery-stage liver-safe GPR40 agonist for type 2 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Liminal Biosciences company profile →
GRI Bio
HQ: United States
Website
- Description: Provider of therapies for inflammatory and autoimmune diseases, including GRI-0621, an oral inhibitor of iNKT cell activity for idiopathic pulmonary fibrosis, and GRI-0803, a novel activator of human type 2 NKT cells for autoimmune disorders with an initial focus on systemic lupus erythematosus, supported by a proprietary library of over 500 compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GRI Bio company profile →
QOL Medical
HQ: United States
Website
- Description: Provider of specialty biopharmaceutical products and services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QOL Medical company profile →
Keryx Biopharmaceuticals
HQ: United States
Website
- Description: Provider of innovative biopharmaceutical medicines, focused on their development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Keryx Biopharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for HepaRegeniX
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to HepaRegeniX
2.2 - Growth funds investing in similar companies to HepaRegeniX
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for HepaRegeniX
4.2 - Public trading comparable groups for HepaRegeniX
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →